Sign in
Not yet taking people in United StatesPhase 1/2

Tests glycerol tributyrate by mouth in adults with MELAS or LHON-Plus

Tests glycerol tributyrate taken by mouth in adults with MELAS or LHON-Plus.

Key facts

Who runs it
George Washington University
Where
Washington D.C., United StatesSee the site
Trial code
Registry title
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
24 people, planned
Starts
Mar 2027
Expected to end
Nov 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Glycerol Tributyrate
Record updated
5 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed gene-based diagnosis of MELAS or LHON-Plus who have symptoms. Everyone takes glycerol tributyrate by mouth.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Symptomatic MELAS or symptomatic LHON-Plus. Complex II enzyme activity must be normal.
Earlier treatment
Cannot join if taking another investigational drug now, or if in another mitochondrial disorder trial within the last six months.
Biomarker or test result
MELAS: m.3243A>G variant, or a mitochondrial variant only in a gene for a Complex I subunit. LHON-Plus: m.11778G>A, or a mitochondrial variant only in a gene for a Complex I subunit.

Main reasons for not taking part

  • History of another primary mitochondrial disorder
  • Acutely ill
  • Pregnant or breastfeeding
  • Current drug or alcohol abuse
  • Has an enteral feeding tube

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Participants must be aged 18 to 65 years
  • A confirmed molecular diagnosis of MELAS or LHON-Plus
  • Symptomatic participants with MELAS harboring the m.3243A>G variant or a mitochondrial pathogenic variant solely mapping in a mitochondrial gene encoding a mitochondrial subunit of Complex I
  • Symptomatic participants with LHON-Plus harboring the m.11778G>A or a mitochondrial pathogenic variant only mapping in a mitochondrial gene encoding a mitochondrial subunit of Complex I
  • Normal enzymatic Complex II activity
  • Participants able to swallow capsules and comply with the requirements of the study according to the opinion of the investigator
  • Able to give written, informed consent
  • Participants who are sexually active and/or fertile must use an effective birth control during the study

Who cannot take part

  • • History of another primary mitochondrial disorder; Participants acutely ill; Positive urine pregnancy test for female subjects of childbearing potential within seven days prior to the first dose of the investigational drug; Pregnancy and/or breastfeeding; Participating in another mitochondrial disorder trial; Participated in another mitochondrial disorder trial within the last six months; On a current therapy with other investigational agents; Absence of neurological symptoms, muscle weakness, or exercise intolerance; Presence of any of the following signs or symptoms in the past six months at grade 3 or higher based on the CTCAE version 4.03: nausea, vomiting, diarrhea, hypoglycemia, hyperglycemia, dizziness, blurred vision, or syncope; A known hypersensitivity to any excipient contained in the drug formulation; Current abuse of drugs and/or alcohol; Unable to consent for themselves; Participants with an enteral feeding tube; Inability to travel to the study site

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Children's National HospitalWashington D.C., United StatesContact: Debra Regier, M.D., Ph.D.Not yet recruiting

About the trial

What the trial wants to find out

This is a parallel arm non-randomized dose-escalation, open-label basket exploratory phase 1 clinical trial where Mitochondrial encephalopathy, lactic acidosis, stroke-like episodes (MELAS) and Leber's hereditary optic neuropathy-Plus (LHON-Plus) participants will undergo simultaneous enrollment in two disease-based arms and receive daily oral doses of glycerol tributyrate to assess its safety and potential for efficacy using clinical, biochemical, and molecular evidence.

Read full original descriptionShow less

This study will utilize a two-month baseline lead-in phase to establish and document the clinical baseline for each participant in both arms in order to compare the molecular and clinical parameters. This is clinically relevant in light of the high clinical heterogeneity among subjects affected by the same mitochondrial disease (MELAS or LHON-Plus). For ethical concerns prompted by the lack of treatment for these two intractable and progressive mitochondrial diseases, there will not be a placebo control group. Thus, each participant will act as their own control and receive oral doses of glycerol tributyrate, eliminating the need for a placebo. Considering the high clinical heterogeneity among participants affected by MELAS or LHON-Plus and some clinical divergence between MELAS and LHON-Plus, this strategy is beneficial to every enrolled participants, as each will receive the investigational drug, glycerol tributyrate. In addition, this approach will determine the subject-specific maximal optimized dose in a personalized medicine-based approach.

After approval of the IRB protocol from the Institutional Review Board Data and signed consent form from all participants, this investigational basket clinical trial has three phases spanning over 20 months:

* A baseline lead-in phase (2 months) to collect participant-specific baseline for clinical, biochemical, molecular and metabolic biomarkers that will be monitored throughout the subsequent dose-escalation and clinical phases. * A dose-escalation phase (6 months) to determine the participant-specific maximum tolerated dose (MTD) during which participant-specific clinical and biochemical biomarkers are collected every month. * A clinical phase at a fixed subject-specific MTD dose (12 months) to collect participant-specific clinical, biochemical, molecular and metabolic biomarkers and to perform three scheduled skin biopsies: at the outset, mid-point, and the end of this clinucal phase. We have planned for a 12-month-long clinical phase at a fixed participant-specific MTD considering the absence of reliable predictors that makes idiosyncratic disease-specific symptoms for MELAS and LHON-Plus impossible to forecast among participant for assessing the potential efficacy of glycerol tributyrate by monitoring clinical symptoms specific for each disease. During the 12-month-long time-frame, disease-specific clinical symptoms will be collected as preliminary evidence of efficacy of glycerol tributyrate using disease-specific biomarkers.

Finally, discharge procedure during which the clinical investigator will record non-serious adverse events or serious adverse events for 7 or 30 days, respectively, after the last day of study participation.

The 2 groups in the trial

  • MELASTreatment being tested

    12 MELAS participants will be enrolled in the baseline phase before being given an oral administration of glycerol tributyrate. All participants will undergo a six-month-long non-randomized dose escalation phase to determine each participant-specific maximum tolerated dose (MTD), after which the fixed MTD of glycerol tributyrate will be orally administered during the 12-month-long clinical phase.

    Treatment: Glycerol Tributyrate

  • LHON-PlusTreatment being tested

    12 LHON-Plus participants will be enrolled and will be given the interventional drug, glycerol tributyrate. All participants will undergo a six-month-long non-randomized dos escalation phase in order to determine the patient-specific maximum tolerated dose (MTD), after which they will be orally administered this MTD for a period of 12 months.

    Treatment: Glycerol Tributyrate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Investigational Study of Glycerol Tributyrate in MELAS and LHON-Plus
Plain-language title
Tests glycerol tributyrate by mouth in adults with MELAS or LHON-PlusGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06792500, who can take part
Record updated
5 October 2026